pubmed.ncbi.nlm.nih.gov

Metabolic effects of bariatric surgery in patients with moderate obesity and type 2 diabetes: analysis of a randomized control trial comparing surgery with intensive medical treatment - PubMed

Randomized Controlled Trial

. 2013 Aug;36(8):2175-82.

doi: 10.2337/dc12-1596. Epub 2013 Feb 25.

Affiliations

Randomized Controlled Trial

Metabolic effects of bariatric surgery in patients with moderate obesity and type 2 diabetes: analysis of a randomized control trial comparing surgery with intensive medical treatment

Sangeeta R Kashyap et al. Diabetes Care. 2013 Aug.

Abstract

Objective: To evaluate the effects of two bariatric procedures versus intensive medical therapy (IMT) on β-cell function and body composition.

Research design and methods: This was a prospective, randomized, controlled trial of 60 subjects with uncontrolled type 2 diabetes (HbA1c 9.7 ± 1%) and moderate obesity (BMI 36 ± 2 kg/m(2)) randomized to IMT alone, IMT plus Roux-en-Y gastric bypass, or IMT plus sleeve gastrectomy. Assessment of β-cell function (mixed-meal tolerance testing) and body composition was performed at baseline and 12 and 24 months.

Results: Glycemic control improved in all three groups at 24 months (N = 54), with a mean HbA1c of 6.7 ± 1.2% for gastric bypass, 7.1 ± 0.8% for sleeve gastrectomy, and 8.4 ± 2.3% for IMT (P < 0.05 for each surgical group versus IMT). Reduction in body fat was similar for both surgery groups, with greater absolute reduction in truncal fat in gastric bypass versus sleeve gastrectomy (-16 vs. -10%; P = 0.04). Insulin sensitivity increased significantly from baseline in gastric bypass (2.7-fold; P = 0.004) and did not change in sleeve gastrectomy or IMT. β-Cell function (oral disposition index) increased 5.8-fold in gastric bypass from baseline, was markedly greater than IMT (P = 0.001), and was not different between sleeve gastrectomy versus IMT (P = 0.30). At 24 months, β-cell function inversely correlated with truncal fat and prandial free fatty acid levels.

Conclusions: Bariatric surgery provides durable glycemic control compared with intensive medical therapy at 2 years. Despite similar weight loss as sleeve gastrectomy, gastric bypass uniquely restores pancreatic β-cell function and reduces truncal fat, thus reversing the core defects in diabetes.

Trial registration: ClinicalTrials.gov NCT00432809.

PubMed Disclaimer

Figures

Figure 1
Figure 1

Glucose (A) and C-peptide (B) during the mixed-meal tolerance test performed at time of randomization (baseline) and at 24 months after randomization for IMT, sleeve gastrectomy, and gastric bypass. Mixed meal consisted of Boost (8 ounces) with 30-min interval blood sampling for glucose and C-peptide values. Data are shown in median values. RYGB, Roux-en-Y gastric bypass.

Similar articles

Cited by

References

    1. Danaei G, Finucane MM, Lu Y, et al. ; Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Blood Glucose) National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants. Lancet 2011;378:31–40 - PubMed
    1. Buchwald H, Oien DM. Metabolic/bariatric surgery Worldwide 2008. Obes Surg 2009;19:1605–1611 - PubMed
    1. Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med 2012;366:1567–1576 - PMC - PubMed
    1. Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med 2012;366:1577–1585 - PubMed
    1. Gatmaitan P, Huang H, Talarico J, et al. Pancreatic islet isolation after gastric bypass in a rat model: technique and initial results for a promising research tool. Surg Obes Relat Dis 2010;6:532–537 - PubMed

Publication types

MeSH terms

Substances